More about

Glycated Hemoglobin A

News
January 22, 2020
3 min read
Save

Rising HbA1c levels contribute to CV event risk in diabetes, CAD

The longitudinal increase of HbA1c was found to be independently associated with elevated incidence of CV events for patients with diabetes and multivessel CAD, according to findings published in JAMA Network Open.

News
January 02, 2020
2 min read
Save

CVD risk evaluation in prediabetes not improved by incorporating HbA1c

Using HbA1c may not alter the effectiveness of screening for cardiovascular disease risk among adults with prediabetes, although CVD risk is greater among this group vs. those with lower HbA1c levels, according to findings published in Diabetes Care.

News
November 27, 2019
2 min read
Save

Aerobic exercise, not diet, improves diastolic function in type 2 diabetes, obesity

PHILADELPHIA — Adults with type 2 diabetes and obesity without CVD experienced dramatic metabolic improvements after a 12-week, low-calorie diet intervention but saw no change in diastolic function, which was only observed with an aerobic exercise intervention, according to data presented at the American Heart Association Scientific Sessions.

News
November 19, 2019
2 min read
Save

Glycemic management possible with small-molecule glucagon receptor antagonist

Among a cohort of adults with type 2 diabetes, HbA1c and fasting plasma glucose were effectively reduced via treatment with the small-molecule glucagon receptor antagonist RVT-1502, according to findings published in Diabetes Care.

News
November 15, 2019
2 min read
Save

Evening eating may worsen heart health in women

PHILADELPHIA — Women who consumed a higher proportion of their daily calories after 6 p.m. had poorer overall CV health and higher BP, BMI and HbA1c levels, researchers reported at the American Heart Association Scientific Sessions.

News
November 13, 2019
5 min read
Save

FDA advisory committee rejects recommending approval of lower-dose empagliflozin for type 1 diabetes

The Endocrinologic and Metabolic Drugs Advisory Committee of the FDA voted 14-2 against recommending approval of a supplemental new drug application for the SGLT2 inhibitor empagliflozin 2.5 mg as an oral medication adjunct to insulin therapy for adults with type 1 diabetes, with committee members citing uncertainty regarding the adjudication of diabetic ketoacidosis and a lack of adequate data to support evidence for safety and efficacy.

News
October 30, 2019
3 min read
Save

PIONEER 8: Oral semaglutide reduces HbA1c, body weight as addition to insulin in type 2 diabetes

Oral semaglutide was shown to be superior to placebo for lowering HbA1c and body weight among adults with type 2 diabetes already taking insulin with or without metformin, according to findings published in Diabetes Care.

News
October 28, 2019
2 min read
Save

Glycated albumin ‘good predictor’ when assessing glucose management

When assessing glycemic management in diabetes, measuring glycated albumin may be a more effective tool than measuring HbA1c, particularly among patients with a recent diabetes diagnosis, according to findings published in the Journal of Diabetes and its Complications.

News
October 24, 2019
4 min read
Save

Hospitalizations, mortality more likely in type 2 diabetes with high HbA1c variability

Mortality and hospitalization risks are higher for adults with type 2 diabetes who experience larger fluctuations in HbA1c or have very high or very low average HbA1c levels, according to findings published in Diabetes Care.

News
October 10, 2019
3 min read
Save

Lower socioeconomic status, more complicated disease influence decision to skip diabetes education sessions

Factors that may impede attendance at diabetes self-management education and support, or DSMES, sessions include lower socioeconomic status, required copayments, higher HbA1c, multiple medications and the use of insulin, according to findings published in Diabetes Educator.

View more